Won Ki Kang
A senior gastric cancer oncologist whose adjuvant and perioperative trials in Korea helped define post-gastrectomy chemotherapy.
Won Ki Kang has led Korean multicentre trials in gastric cancer including the ARTIST studies of adjuvant chemoradiation and has been an investigator on first-line immunotherapy and HER2 trials.
| Title | Journal | Year |
|---|---|---|
| Phase III trial of adjuvant capecitabine/cisplatin with or without radiotherapy in D2-resected gastric cancer (ARTIST) | Journal of Clinical Oncology | 2012 |
Pages like this
not linked directly; found by shared links- PersonJeeyun Lee
Shares Samsung Medical Center, Gastric & gastro-oesophageal junction cancer.
- PersonYelena Y. Janjigian
Shares CheckMate 649, Gastric & gastro-oesophageal junction cancer.
- ProductCAPOX (capecitabine, oxaliplatin)
Shares CheckMate 649, Gastric & gastro-oesophageal junction cancer.
- IdeaBiomarker-directed first-line quadruplets in gastric cancer
Shares CheckMate 649, Gastric & gastro-oesophageal junction cancer.
- InstitutionKorean Cancer Study Group
Shares Samsung Medical Center, Gastric & gastro-oesophageal junction cancer.
- ProductFOLFOX (5-FU, leucovorin, oxaliplatin)
Shares CheckMate 649, Gastric & gastro-oesophageal junction cancer.
- TermCombined positive score (CPS)
Shares CheckMate 649, Gastric & gastro-oesophageal junction cancer.